Vera Therapeutics announced that its ORIGIN Phase 3 trial of atacicept for IgA nephropathy met its primary endpoint, showing statistically significant and clinically meaningful reductions in ...

MRT-6160 inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly, ...

The APPLAUSE-IgAN results demonstrate that targeted, disease-modifying therapy can preserve long-term kidney function.

Greater disease activity and higher proteinuria levels were associated with a greater risk for VTE among patients with LN.

The ORIGIN Phase 3 trial met the primary endpoint with a statistically significant and clinically meaningful reduction in ...

Travere Therapeutics (TVTX) announced that the Company will present 11 abstracts, including a late-breaking poster, at the upcoming American ...

Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys") today announced that it has reached an agreement with the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan regarding ...

Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings ...

Investigators studied IgA nephropathy relapse, its correlation with kidney failure, and risk factors using a prospective cohort.

Notably, 2 deaths occurred in the iscalimab group, 1 due to urosepsis and another associated with macrophage-activation syndrome. Opportunistic infections, including tuberculosis and herpes zoster, ...

The US regulator has provided clearance for PainChek's digital app for pain detection, thus opening a US$100 million a year ...

The presence of additional proteins in urine leads to foamy urine as a primary cause. The normal function of kidneys prevents proteins from entering urine, but damage to these organs allows proteins ...